Ascendis Pharma (ASND) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma A/S reported a net loss for the first half of 2024, despite generating revenue. Significant investments in research and development, as well as selling, general, and administrative expenses, led to an operating loss. Losses per share were reported for both the three-month and six-month periods ended June 30, 2024.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.